Centre for Virology, Vaccinology and Therapeutics

Name

Centre for Virology, Vaccinology and Therapeutics

Legal name

Centre for Virology, Vaccinology and Therapeutics Limited

Website

https://cvvt.hk

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Government Research Funding: CVVT is funded by the Innovation and Technology Commission (ITC) of the HKSAR Government through the InnoHK initiative, supporting its research operations and infrastructure at Hong Kong Science and Technology Park
2. Licensing and Technology Transfer: CVVT licenses its proprietary technologies (vaccines, therapeutics, diagnostics, organoid platforms) to spinoff companies and commercial partners for further development and market launch
3. Drug Discovery Services: CVVT offers fee-for-service drug discovery platform services including NMR analysis, LC-MS metabolomics, and virtual screening to academic and industry clients

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

CVVT is a Hong Kong-based research center that develops vaccines, antivirals, and diagnostics for infectious diseases. It operates research platforms spanning vaccine development, broadly neutralizing antibodies, organoid-based disease modeling, and an integrated drug discovery service combining NMR, LC-MS, and virtual screening. Its technologies are commercialized through licensing to spinoff companies and through fee-for-service drug discovery engagements.

Product overview

CVVT operates as a research center under the Health@InnoHK initiative, offering a suite of interconnected research platforms and services rather than a unified software product. The core offerings include: the Drug Discovery Platform providing NMR, LC-MS, and virtual screening services; the Human Respiratory Organoid Platform enabling disease modeling and drug testing; the Vaccine Development Platform supporting multiple vaccine modalities; and the Automated Multiplex Diagnostics for pathogen detection. These are complemented by five spinoff companies (HKUBio, BiomOrgan, HKUV, Orimmune, Antenovus) that commercialize specific technologies developed at CVVT. The center bridges basic research with translational applications, particularly focused on infectious disease control and prevention in the Guangdong-Hong Kong-Macao Greater Bay Area.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Discovery Platform End-to-end drug discovery service integrating Nuclear Magnetic Resonance (NMR), Liquid Chromatography-Mass Spectrometry (LC-MS), and in silico virtual screening. Offers drug-target interaction studies, metabolomics/lipidomics analysis, and virtual screening of chemical libraries ranging from 300,000 to 10 billion compounds for academic and industry clients.
• Human Respiratory Organoid Platform Proprietary platform providing long-term expandable human respiratory organoid culture systems spanning the entire respiratory tract, including nasal, tracheal, and alveolar models. Used for disease modeling, drug testing, and variant behavior studies by academic and industry partners.
• Vaccine Development Platform Multi-technology vaccine development platform encompassing DelNS1 live attenuated vaccine system, PD-1 based T cell vaccine, mucosal RNA-scaffold-protein vaccine, reverse genetically engineered mucosal vaccine, and mucosal vaccines for bacterial super-infections. Licensed to spinoff companies and partners for further development.
• Automated Syndrome-based Multiplex Diagnostic Panels Automated rapid multiplex system capable of detecting up to 40 pathogen targets simultaneously. Designed for emerging global health challenges and syndrome-based diagnosis in clinical and surveillance settings.
• Anitch Eczema Management Series with Anesinin Eczema management products featuring the Anesinin plant-based composite formula developed by the HKU research team. The formula inhibits virulence factors of Staphylococcus aureus without destroying the microbiome, offering a drug-free alternative for eczema patients. Commercially launched at Watsons Hong Kong.
• PDOHub HK Precision Medicine Services Patient-Derived Organoid Hub providing tumor organoid drug sensitivity testing and organoid-based research services for oncology and infectious diseases. Offers personalised treatment insights for esophageal, stomach, colorectal, triple-negative breast, and lung cancers to clinicians and patients.

Quantifiable outcome

• Eczema affects 1 in 5 Hong Kong residents; Anitch products launched at Watsons HK offer a drug-free alternative targeting approximately 800 million eczema patients worldwide
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

Nine partnerships are on record, tiered flagship, core and minor.

• BiomOrgan Limited (比幹生物)flagshipStrategic or Co-development Partner · 31 March 2026BiomOrgan, a HKU and CVVT life science spin-off founded in 2021 at Hong Kong Science and Technology Parks, provides the scientific foundation for PDOHub HK operations. It contributes its patented respiratory organoid platform for tumour organoid services and infectious disease applications. BiomOrgan and CVVT jointly lead business development and market engagement for PDOHub, expanding its presence locally and internationally.
• MGI Tech Co., Ltd. (华大智造)coreTechnology or Integration · 31 March 2026MGI Tech, a Shenzhen-based genomics company founded in 2016, empowers PDOHub HK by co-developing automation systems for organoid-based antibody testing and providing high-throughput sequencing platforms for patient-derived organoids. MGI contributes its proprietary sequencing capabilities and intelligent laboratory workflows to enable high-quality, data-driven precision medicine insights.
• Professor Dora Kwong (鄺麗雲)coreStrategic or Co-development Partner · 31 March 2026Professor Dora Kwong, Clinical Professor of Clinical Oncology at HKUMed, serves as PDOHub Honorary Clinical Advisor (Oncology). She provides clinical insights to advance patient-centred tumour-organoid applications, guiding therapeutic agent selection, clinical study design, and translational research focus areas including early detection, treatment stratification, and long-term outcomes.
• Antenovus Biotechnology LimitedflagshipStrategic or Co-development Partner · 12 February 2026Antenovus is a HKU biotechnology startup dedicated to providing natural, sustainable, non-antibiotic solutions to combat microbial infections and related diseases. It commercialises the Anesinin technology developed by HKU research team via the Anitch brand, which was launched at Watsons Hong Kong in February 2026.
• Watsons Hong KongcoreChannel Partner/ Reseller/ Distributor · 12 February 2026Watsons Hong Kong, a health and beauty retailer, serves as the retail distribution partner for Anitch eczema care products featuring Anesinin. Vincent Lo, Chief Pharmacist of Watsons Hong Kong, highlighted the partnership's role in providing science-backed solutions to the community for long-term eczema management.
• Orimmune BioTech LimitedflagshipStrategic or Co-development PartnerOrimmune is a CVVT spinoff company focusing on next-generation immunotherapy, presenting its Anti-Δ42PD1 Antibody Platform at ASGH 2026. The platform is specifically designed to tackle tumours resistant to current PD-1 inhibitors, offering superior outcomes for liver cancer (HCC).
• The University of Hong Kong (HKU)coreStrategic or Co-development PartnerCVVT was established in collaboration with the Department of Microbiology of the University of Hong Kong in 2020. The centre leverages HKU's research talent, facilities, and academic infrastructure. Multiple CVVT Programme Leaders and Principal Investigators hold appointments at HKU's LKS Faculty of Medicine.
• Hubrecht Institute (Amsterdam, Netherlands)minorStrategic or Co-development PartnerListed as a collaborator on CVVT's About Us page, representing an international academic partnership in the field of organoid research and development.
• Hong Kong Science and Technology Parks Corporation (HKSTP)coreStrategic or Co-development PartnerCVVT is physically located at the Hong Kong Science and Technology Park, which provides infrastructure, ecosystem support, and connectivity to other biotech companies within the park. Mr Terry Wong, CEO of HKSTP, participated in the Anitch product launch ceremony.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Wyss Institute for Biologically Inspired Engineering: Wyss Institute is Harvard's translational research institute developing novel biotechnologies including organoids, biomimetic chips, and therapeutic platforms. It is comparable to CVVT as a university-affiliated research centre translating breakthrough science into commercial applications via spinoff companies and licensing.
• Hubrecht Institute: Hubrecht Institute is a world-leading organoid research institute in the Netherlands and a current CVVT collaborator. It is directly comparable as both organisations develop and commercialise organoid technology platforms for disease modelling and translational research, with overlapping scientific leadership in the organoid field.
• Pasteur Institute: The Pasteur Institute is a globally renowned virology and vaccinology research centre with a similar focus on infectious disease prevention and vaccine development. It serves as a directly comparable model for CVVT, combining basic research with translational applications and operating a network of spinoff companies to commercialise discoveries.
• Crown Bioscience: Crown Bioscience is a global contract research organisation providing preclinical drug discovery services including organoid-based disease models and oncology screening. It is directly comparable to CVVT's BiomOrgan spinoff and drug discovery platform services, serving similar pharma and biotech clients with organoid and in vitro disease modelling capabilities.
• Scripps Research: Scripps Research is a leading non-profit biomedical research organisation with strong virology, immunology, and therapeutic antibody programmes. It is comparable to CVVT as a research institution developing broadly neutralising antibodies, antivirals, and novel vaccine platforms, with technology licensing as a key commercialisation channel.

Broad incumbents

• BioNTech: BioNTech is a major commercial vaccine and therapeutics developer with mRNA technology platforms targeting infectious diseases and oncology. It is comparable to CVVT's vaccine and antibody programmes as a broad incumbent operating at significantly greater commercial scale with established global partnerships.
• WuXi AppTec: WuXi AppTec is a leading global contract research and development organisation offering drug discovery, preclinical, and clinical services across therapeutic areas. It serves as a broad incumbent comparable to CVVT's drug discovery platform services but operates at vastly greater scale across multiple geographies and modalities.
• Moderna: Moderna is a leading commercial vaccine developer with an established mRNA vaccine platform targeting respiratory viruses including COVID-19, influenza, and RSV. It serves as a broad incumbent comparable to CVVT's vaccine development programmes but operates at vastly greater commercial scale with approved products and global distribution.

Emerging players

• Sino Biological: Sino Biological is a China-based biotechnology company providing recombinant proteins, antibodies, and reagents for infectious disease and vaccine research. It is comparable to CVVT as an Asia-Pacific biotech research tools and services provider supporting similar pharmaceutical and academic customers in virology and immunology.
• ATCC: ATCC is a global biological materials resource centre providing cell lines, organoid models, and research reagents to academic and industry researchers. It is comparable to CVVT's organoid platform offerings as a provider of standardised biological research tools, though with a much broader catalogue of non-virology products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/cvvt.hk
• LinkedInlinkedin.com/company/centre-for-virology-vaccinology-and-therapeutics
• Instagraminstagram.com/cvvt.hk

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Virology, Vaccinology and Therapeutics